<DOC>
	<DOCNO>NCT00080301</DOCNO>
	<brief_summary>The purpose clinical research study learn BMS-247550 add approve therapy capecitabine well capecitabine alone shrink slow growth cancer woman metastatic breast cancer resistant taxane receive anthracycline chemotherapy . The safety treatment also study .</brief_summary>
	<brief_title>Novel Epothilone Plus Capecitabine Versus Capecitabine Alone Patients With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Patients must receive either 2 3 prior chemotherapy regimen include adjuvant neoadjuvant therapy . Prior treatment must include anthracycline ( i.e. , doxorubicin epirubicin ) taxane ( i.e. , paclitaxel docetaxel ) . Patients must receive minimum cumulative dose anthracycline must resistant anthracycline . Patients must resistant taxane therapy . Patients may history brain and/or leptomeningeal metastasis . Patients may CTC Grade 2 great neuropathy ( motor sensory ) . Patients may prior treatment epothilone and/or capecitabine ( i.e. , Xeloda )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
</DOC>